# EDGAR Filing Document

**Accession Number:** 0001581280
**File Stem:** 0001581280-26-000012
**Filing Date:** 2026-1
**Character Count:** 13714
**Document Hash:** 92052ecde16a43e3f70bf53b6b75593b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001581280-26-000012.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001581280-26-000012

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Twist Bioscience Corp
- **CENTRAL INDEX KEY:** 0001581280
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462058888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38720
- **FILM NUMBER:** 26524778

**BUSINESS ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 800-719-0671

**MAIL ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? twist-20260112

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**January 12, 2026**

**Twist Bioscience Corporation**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38720** | **46-2058888** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(I. R. S. Employer**<br>**Identification No.)** |

---

**681 Gateway Boulevard**

**South San Francisco, CA 94080**

**(Address of principal executive offices, including ZIP code)**

**(800) 719-0671**

**(Registrant's telephone number, including area code)**

**Not Applicable** 

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common Stock** | **TWST** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02Results of Operations and Financial Condition.**

On January 12, 2026, Twist Bioscience Corporation (the "<u>Company</u>") issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company's revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and are subject to change based on the completion of ongoing internal control, review and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company's unaudited condensed financial statements for the fiscal quarter ended December 31, 2025. Accordingly, stockholders should not place undue reliance on this preliminary estimate.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit No.** | **Description** |
| &nbsp;&nbsp;99.1 | <u>[Press release dated January 12, 2026 titled "Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue"](twst-prexannouncementprxex.htm)</u> |
| &nbsp;&nbsp;104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: January 12, 2026 | **Twist Bioscience Corporation** |
| | /s/ Judy Yan |
| | Judy Yan |
| | Assistant General Counsel and Assistant Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_2.jpg](image_2.jpg)

**Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue**

**SOUTH SAN FRANCISCO, Calif. --** January 12, 2026 – <u>Twist Bioscience Corporation</u> (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025.

**Fiscal 2026 First Quarter Preliminary, Unaudited Revenue**

Total revenue for the first quarter of fiscal 2026 grew 17% to approximately $103.7 million (+/- $0.2 million) compared to the same period of fiscal 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• DNA Synthesis and Protein Solutions revenue grew 27% to approximately $51.1 million (+/- $0.1 million) for the first quarter of fiscal 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• NGS Applications revenue grew to approximately $52.6 million (+/- $0.1 million) for the first quarter of fiscal 2026, ahead of guidance expectations.

"We are starting the fiscal year strong with more than $103 million in revenue, growth of 17%, coming in ahead of our guidance of $100 to $101 million," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "We're encouraged by our overall revenue growth as well as the momentum from DNA Synthesis and Protein Solutions and NGS Applications. Excluding one large NGS Applications customer who is transitioning their assay from research to commercial, NGS Applications revenue grew 18% compared to same period of the year prior. We see continued momentum and reacceleration of the NGS segment as expected moving into our fiscal second quarter."

Dr. Leproust will present today at the J.P. Morgan 2026 Healthcare Conference at 2:15 p.m. Pacific Time. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website <u>here</u>.

Twist will issue its financial results for the first quarter of fiscal 2026 before the opening of the market on February 2, 2026, and will hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time. The conference call will be webcast live through the Investor Relations section under the "Company" tab at <u>www.twistbioscience.com</u>. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking <u>here</u>. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

**About Twist Bioscience**

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of

------

the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit <u>www.twistbioscience.com</u>.

Follow us on LinkedIn \| X \| YouTube \| Instagram \| Bluesky

**Preliminary and Unaudited Nature of Reported Results**

Twist Bioscience's revenue expectations for the fiscal quarter ended December 31, 2025 are preliminary, unaudited and are subject to change based on the completion of ongoing internal control, review and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in Twist Bioscience's unaudited condensed financial statements for the fiscal quarter ended December 31, 2025. Accordingly, you should not place undue reliance on this preliminary estimate.

**Twist Bioscience Legal Notice Regarding Forward-Looking Statements**

This press release contains forward-looking statements, including statements relating to expectations for future performance and certain preliminary, unaudited results for the fiscal quarter ended December 31, 2025, including estimated revenue for DNA Synthesis and Protein Solutions and NGS Applications. There can be no assurance that the company's actual financial results for the fiscal quarter ended December 31, 2025 will not differ from these estimates, including as a result of completion of the company's closing procedures and final adjustments, and other developments that may arise between the date of this press release and the time the company's financial results for such period are finalized, and any such changes could be material. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and

------

machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

**CONTACTS:**

**For Investors:**

Angela Bitting

SVP, Corporate Affairs

925-202-6211

<u>abitting@twistbioscience.com</u>

**For Media:**

Amanda Houlihan

Communications Manager

774-265-5334

<u>ahoulihan@twistbioscience.com</u>

<br>